<SEC-DOCUMENT>0001231919-25-000550.txt : 20251125
<SEC-HEADER>0001231919-25-000550.hdr.sgml : 20251125
<ACCEPTANCE-DATETIME>20251125180354
ACCESSION NUMBER:		0001231919-25-000550
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251121
FILED AS OF DATE:		20251125
DATE AS OF CHANGE:		20251125

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GADICKE ANSBERT
		CENTRAL INDEX KEY:			0001134655
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522990

	MAIL ADDRESS:	
		STREET 1:		399 BOYLSTON STREET
		STREET 2:		SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MPM ASSET MANAGEMENT LLC
		CENTRAL INDEX KEY:			0001263048
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522984

	BUSINESS ADDRESS:	
		STREET 1:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6174259200

	MAIL ADDRESS:	
		STREET 1:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MPM BioImpact LLC
		CENTRAL INDEX KEY:			0001687078
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522986

	BUSINESS ADDRESS:	
		STREET 1:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6174259200

	MAIL ADDRESS:	
		STREET 1:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER NAME:	
		FORMER CONFORMED NAME:	BioImpact Capital LLC
		DATE OF NAME CHANGE:	20210831

	FORMER NAME:	
		FORMER CONFORMED NAME:	MPM Oncology Impact Management LP
		DATE OF NAME CHANGE:	20161007

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MPM Oncology Innovations Fund GP LLC
		CENTRAL INDEX KEY:			0001857903
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522985

	BUSINESS ADDRESS:	
		STREET 1:		C/O MPM BIOIMPACT
		STREET 2:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-425-9200

	MAIL ADDRESS:	
		STREET 1:		C/O MPM BIOIMPACT
		STREET 2:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MPM ONCOLOGY INNOVATIONS FUND LP
		CENTRAL INDEX KEY:			0001719960
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522989

	BUSINESS ADDRESS:	
		STREET 1:		450 KENDALL STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-425-9200

	MAIL ADDRESS:	
		STREET 1:		450 KENDALL STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER NAME:	
		FORMER CONFORMED NAME:	MPM ONCOLOGY INNOVATIONS FUND L.P.
		DATE OF NAME CHANGE:	20171017

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Oncology Impact Fund (Cayman) Management L.P.
		CENTRAL INDEX KEY:			0001721036
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522987

	BUSINESS ADDRESS:	
		STREET 1:		450 KENDALL STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		6174259200

	MAIL ADDRESS:	
		STREET 1:		450 KENDALL STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			UBS Oncology Impact Fund L.P.
		CENTRAL INDEX KEY:			0001691428
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40366
		FILM NUMBER:		251522988

	BUSINESS ADDRESS:	
		STREET 1:		399 BOYLSTON STREET
		STREET 2:		SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-425-9200

	MAIL ADDRESS:	
		STREET 1:		399 BOYLSTON STREET
		STREET 2:		SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02142

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Werewolf Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001785530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				823523180
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		200 TALCOTT AVENUE
		STREET 2:		2ND FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-952-0555

	MAIL ADDRESS:	
		STREET 1:		200 TALCOTT AVENUE
		STREET 2:		2ND FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-11252025_111145.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-11-21</periodOfReport>

    <issuer>
        <issuerCik>0001785530</issuerCik>
        <issuerName>Werewolf Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>HOWL</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001134655</rptOwnerCik>
            <rptOwnerName>GADICKE ANSBERT</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>true</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001719960</rptOwnerCik>
            <rptOwnerName>MPM ONCOLOGY INNOVATIONS FUND LP</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001691428</rptOwnerCik>
            <rptOwnerName>UBS Oncology Impact Fund L.P.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001721036</rptOwnerCik>
            <rptOwnerName>Oncology Impact Fund (Cayman) Management L.P.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001687078</rptOwnerCik>
            <rptOwnerName>MPM BioImpact LLC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001857903</rptOwnerCik>
            <rptOwnerName>MPM Oncology Innovations Fund GP LLC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001263048</rptOwnerCik>
            <rptOwnerName>MPM ASSET MANAGEMENT LLC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM BIOIMPACT LLC</rptOwnerStreet1>
            <rptOwnerStreet2>399 BOYLSTON STREET, SUITE 1100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02116</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-21</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>64331</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.83</value>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5257105</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnotes</value>
                    <footnoteId id="F4"/>
                    <footnoteId id="F5"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-24</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>88802</value>
                    <footnoteId id="F6"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.98</value>
                    <footnoteId id="F7"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5168303</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnotes</value>
                    <footnoteId id="F4"/>
                    <footnoteId id="F8"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-25</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>42533</value>
                    <footnoteId id="F9"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.92</value>
                    <footnoteId id="F10"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5125770</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnotes</value>
                    <footnoteId id="F4"/>
                    <footnoteId id="F11"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.</footnote>
        <footnote id="F2">The shares were sold as follows: 4,417 by MPM Asset Management LLC (&quot;AM LLC&quot;), 27,904 by MPM BioVentures 2014, L.P. (&quot;BV 2014&quot;), 1,861 by MPM BioVentures 2014(B), L.P. (&quot;BV 2014(B)&quot;), 960 by MPM Asset Management Investors BV2014 LLC (&quot;AM
BV2014&quot;), 6,145 by MPM Oncology Innovations Fund, L.P. (&quot;MPM OIF&quot;) and 23,044 by UBS Oncology Impact Fund L.P. (&quot;UBS Oncology&quot;).</footnote>
        <footnote id="F3">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F4">MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (&quot;BV LLC&quot;) are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC (&quot;MPM OIF GP&quot;) is the
general partner of MPM OIF. MPM BioImpact LLC (&quot;BioImpact&quot;) is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager
of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.</footnote>
        <footnote id="F5">The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology.</footnote>
        <footnote id="F6">The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology.</footnote>
        <footnote id="F7">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F8">The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology.</footnote>
        <footnote id="F9">The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology.</footnote>
        <footnote id="F10">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the
Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F11">The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology.</footnote>
    </footnotes>

    <remarks>This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2014, L.P.</remarks>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC, the GP of MPM Oncology Innovations Fund, L.P.</signatureName>
        <signatureDate>2025-11-25</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC</signatureName>
        <signatureDate>2025-11-25</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC</signatureName>
        <signatureDate>2025-11-25</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke, member of MPM Asset Management LLC</signatureName>
        <signatureDate>2025-11-25</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke</signatureName>
        <signatureDate>2025-11-25</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund, L.P.</signatureName>
        <signatureDate>2025-11-18</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P.</signatureName>
        <signatureDate>2025-11-25</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
